NLRC4-deficient mice with NAFLD also showed decreased tumor-associated macrophages (TAMs) and reduced IL-1β and VEGF expression, highlighting NLRC4’s role in managing the growth and recurrence of liver metastases in the context of both NAFLD and colorectal cancer [121]. This evidence concerns the gene IL1B and metabolic dysfunction-associated steatotic liver disease.